The relationship between inflammatory factors and the risk of breast cancer in Kailuan cohort
10.16462/j.cnki.zhjbkz.2019.05.005
- Author:
Gang WANG
1
;
Ni LI
;
Xiao-shuang FENG
;
Zhang-yan LV
;
Luo-pei WEI
;
Xin LI
;
Yu-heng CHEN
;
Lan-wei GUO
;
Hong-da CHEN
;
Jian YIN
;
Hong CUI
;
Jian-song REN
;
Shou-ling WU
;
Ju-fang SHI
;
Min DAI
;
Jie HE
Author Information
1. Department of Oncology
- Publication Type:Research Article
- Keywords:
C-reactive protein;
Neutrophils;
Breast neoplasms;
Cohort studies
- From:
Chinese Journal of Disease Control & Prevention
2019;23(5):517-521
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate whether elevated baseline levels of high sensitivity C-Reactive Protein (hsCRP) and neutrophil (NE) are associated with an increased risk of breast cancer in Kailuan female cohort. Methods Females from Kailuan cohort (2006-2007) were included in this study. Information on check-up, hsCRP and NE were collected at baseline for all subjects. Multivariable Cox proportional hazards regression models were used to calculate hazard ratios (HR) and 95% confidence intervals (95%CI) of association between baseline hsCRP and NE values and breast cancer risk. Results By December 31, 2015, a total of 18 866 participants were enrolled in this study. During the follow-up, 183 new cases of breast cancer were observed. All participants were divided into three groups according to the level of hsCRP (<1 mg/L, 1-3 mg/L and >3 mg/L). The cumulative incidence of breast cancer were 829/105, 1 211/105 and 1 495/105 in these 3 groups, respectively ( 2=12.08， P=0.002). Compared with participants with lower hsCRP levels (<1 mg/L), individuals with the highest hsCRP (>3 mg/L) levels had significantly increased risk of breast cancer (HR=1.71,95%CI: 1.18-2.47, P=0.005), howerver, we didn’t find the statistically significant association between NE level (<3.70×109/Lvs. ≥3.70×109/L) and the risk of brease cancer (P>0.05). Conclusions Elevated levels of hsCRP at baseline might increase the risk of breast cancer in females.
